Scarica l'app Stockscreener
22.04
0.45%
-0.10
Dopo l'orario di chiusura:
22.09
0.05
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
US CDC ACIP Puts GSK’s Penmenvy Even With Pfizer, Prepares For Infant MedQuadFi, Lyme Vaccines - insights.citeline.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025) - 24/7 Wall St.
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline - Benzinga
Wolfe Research Adjusts Pfizer Price Target to $22 From $25, Keeps Underperform Rating - marketscreener.com
Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights - GlobeNewswire Inc.
BofA Securities Adjusts Price Target on Pfizer to $26 From $29, Maintains Neutral Rating - marketscreener.com
Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5% - Insider Monkey
How a scrapped Pfizer drug became a winner for SpringWorks - PharmaVoice
Pfizer: Is The Dividend Yield Worth The Effort? - Seeking Alpha
Dermatomyositis Drug Market Deep Research 2025-2032 | Pfizer - openPR.com
Heparin Calcium Market Detailed In New Research Report 2025 | - openPR.com
How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock - Benzinga
Pfizer (PFE) Faces Activist Pressure from Starboard Value - GuruFocus
Pfizer Inc. (PFE): Among Jeff Smith’s Top Activist Targets - Insider Monkey
Trump’s executive order on drug pricing; Pfizer drops oral obesity drug; Seed rounds at their lowest in years; and more - Endpoints News
Pfizer Inc. - Britannica
ACE Inhibitor Market Set to Witness Significant Growth by 2025-2032 | Pfizer Inc.,Merck & Co., Inc.,Novartis AG - openPR.com
Xylose Absorption Test Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Bristol-Myers Squibb Company - openPR.com
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock? - Nasdaq
Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic - Yahoo Finance
Pfizer (PFE) Laps the Stock Market: Here's Why - Yahoo Finance
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III - BioWorld MedTech
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Yahoo Finance
Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
GSK Zantac Appeal Gets Tough Questions From Some US Judges - Bloomberg.com
U.S. Unfractionated Heparin Market Is Booming Worldwide 2025-2032 | Pfizer, Inc., Sagent Pharmaceuticals - openPR.com
Neuroendocrine Tumor Treatment Market Is Booming Worldwide | - openPR.com
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Pfizer, GSK to gain as CDC ACIP votes for RSV shots (NYSE:PFE) - Seeking Alpha
It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope - simplywall.st
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - marketscreener.com
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
0.06%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):